title: MicroRNA301 is a potential diagnostic biomarker for hepatocellular cancer.
abstract: We explored microRNA301 diagnosis value in hepatocellular cancer (HCC), attempting to provide novel insights for early detection, effective prevention, and timely treatment. 42 patients with HCC and 38 controls composed of 9 liver cirrhosis (LC), 9 chronic hepatitis B (CHB) and 20 healthy individuals were investigated in the study. Serum microRNA301 expression levels were detected using fluorescent quantitative polymerase chain reaction (FQ-PCR) technology. ROC curve was performed to evaluate diagnosis value of microRNA301. Meanwhile, the correlations of microRNA301 levels with clinical characteristics were also analyzed. Significantly up-regulated expression of serum microRNA301 was seen in HCC patients compared with the controls (P<0.05). We also noted that level changes of microRNA301 were associated with differentiation, alpha fetoprotein (AFP), portal vein-emboli and HasAg (P<0.05), rather than age, gender and tumor size. Based on the area under ROC curve of 0.880, the critical value of microRNA301 was 2.3530 and the sensitivity and specificity were 88.1% and 70.3%, respectively. The results of this study revealed that microRNA301 might function as a potential diagnostic biomarker for HCC.
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University Guangzhou, China ; Department of Hepatobiliary Surgery, Zhongshan People's Hospital Zhongshan, China.
authors.forename: Kun
authors.initials: K
authors.lastname: He
authors.affiliation: Department of Hepatobiliary Surgery, Zhongshan People's Hospital Zhongshan, China.
authors.forename: Zemin
authors.initials: Z
authors.lastname: Hu
authors.affiliation: Department of Hepatobiliary Surgery, Zhongshan People's Hospital Zhongshan, China.
authors.forename: Jiahou
authors.initials: J
authors.lastname: Ruan
authors.affiliation: Department of Hepatobiliary Surgery, Zhongshan People's Hospital Zhongshan, China.
authors.forename: Qianhong
authors.initials: Q
authors.lastname: Ma
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University Guangzhou, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Zhong
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University Guangzhou, China.
authors.forename: Xinsheng
authors.initials: X
authors.lastname: Cheng
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University Guangzhou, China.
authors.forename: Shibo
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University Guangzhou, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhou
mesh_terms: D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D012372:ROC Curve; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C550735:MIRN301A microRNA, human; D035683:MicroRNAs
keywords: Hepatocellular cancer; MicroRNA301; diagnosis